BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19229704)

  • 1. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
    Tashkin DP; Pearle J; Iezzoni D; Varghese ST
    COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
    Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
    Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender.
    Tashkin DP; Varghese ST
    Pulm Pharmacol Ther; 2011 Feb; 24(1):147-52. PubMed ID: 20659577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
    Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
    Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
    Salvi S; Brashier B; Gothi D; Karkhanis V; Madas S; Gogtay J; Joshi J
    Pulm Pharmacol Ther; 2014 Feb; 27(1):90-5. PubMed ID: 23752057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD.
    Terzano C; Petroianni A; Conti V; Ceccarelli D; Graziani E; Sanduzzi A; D'Avelli S
    Respir Med; 2008 Dec; 102(12):1701-7. PubMed ID: 18760583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
    Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
    Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
    Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
    Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
    Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
    Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
    Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S; Eberlein M; Eckhoff J; Schirren J
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
    Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.